IDEXX Laboratories, Inc. vs iShares Semiconductor ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while iShares Semiconductor ETF trades at $559.4 (market cap $48.19B). The key difference: iShares Semiconductor ETF is the larger of the two by market cap, and iShares Semiconductor ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and iShares Semiconductor ETF for 46 Days on average.
| IDXX | SOXX | |
|---|---|---|
Market Cap | $40.43B | $48.19B |
Volume | 692,164 | 10,257,578 |
Sector | Health | Sector/Thematic |
52-Week High | $766.68 | $655.01 |
52-Week Low | $504.70 | $268.10 |
Typical Hold Time | 46 Days | 46 Days |
Enterprise Value | $41.32B | — |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
SOXX trades at $563.28, down 3.37% on the day, with bullish technical signals from moving averages and a neutral oscillator reading. The ETF faces mixed sentiment with positive AI-driven earnings momentum countered by valuation concerns and Michael Burry's expanded short positions. Recent news highlights strong September performance driven by chip stock gains and AI infrastructure demand projections.
The semiconductor ETF's outlook hinges on sustained AI demand growth versus elevated valuations. BofA projects the global chip market to nearly double by 2030, providing fundamental support, but concentration risk and potential multiple compression present headwinds. Earnings growth remains the key catalyst for further upside from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →